Ribomic

Ribomic Current Liabilities

The Current Liabilities of Ribomic (4591.T) as of Oct 30, 2026 is 135.09 M JPY. In the previous year, Current Liabilities was 153.26 M JPY — a change of -11.85% (lower).

Current Liabilities

135.09 MJPY

YoY

-11.85%

Last updated:

Current Liabilities of Ribomic is 2026 135.09 M JPY. Current Liabilities of Ribomic was 2025 153.26 M JPY. It decreases by -11.85% lower compared to the previous year.

The Ribomic Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
79.83 M JPY
Jan 1, 2020
70.16 M JPY
Jan 1, 2021
89.56 M JPY
Jan 1, 2022
238.10 M JPY
Jan 1, 2023
178.48 M JPY
Jan 1, 2024
167.00 M JPY
Jan 1, 2025
153.26 M JPY
Jan 1, 2026
135.09 M JPY
The Ribomic Current Liabilities history
YEARCurrent LiabilitiesYoY
135.09 MJPY-11.85%
153.26 MJPY-8.23%
167.00 MJPY-6.43%
178.48 MJPY-25.04%
238.10 MJPY+165.85%
89.56 MJPY+27.64%
70.16 MJPY-12.11%
79.83 MJPY-15.05%
93.97 MJPY+84.81%
50.85 MJPY-66.73%
152.85 MJPY-18.05%
186.51 MJPY+29.02%
144.57 MJPY+250.20%
41.28 MJPY-23.99%
54.31 MJPY+0.95%
53.80 MJPY-32.67%
79.90 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Current Liabilities of Ribomic is 135.09 M JPY in 2026.

Current Liabilities of Ribomic changed from 153.26 M JPY to 135.09 M JPY, representing a -11.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Ribomic since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ribomic

All Key Metrics — Ribomic